UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Dec

06

UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting

Read More Share:linkedin| twitter| email

Nov

26

UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

Read More Share:linkedin| twitter| email

Nov

20

Closing gaps in HS care through community engagement and scientific innovation

Read More Share:linkedin| twitter| email

Nov

20

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

Read More Share:linkedin| twitter| email

Nov

14

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

Read More Share:linkedin| twitter| email

Nov

14

A Bright Future: Prioritizing Early Diagnosis, Maintenance, and Remissions in Rheumatology

Read More Share:linkedin| twitter| email

Oct

15

Powering the dreams of people impacted by myasthenia gravis (MG)

Read More Share:linkedin| twitter| email

Oct

15

UCB announces U.S. launch of UCB Myasthenia Gravis Scholarship™ for people impacted by myasthenia gravis in the U.S.

Read More Share:linkedin| twitter| email

Oct

14

UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of BIMZELX® (bimekizumab-bkzx)

Read More Share:linkedin| twitter| email

Oct

11

UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)